What question did this study set out to answer?

This research aims to understand how chromosome 1p/19q deletions influence the response and outcomes of low-grade gliomas treated with temozolomide chemotherapy.

May 22, 2007NeurologyOpen Access

Temozolomide for low-grade gliomas

View Full Paper

Ask AI

Bookmark

Authors

GKGentian KaloshiUniversité Claude Bernard Lyon 1 ABAlexandra Benouaich‐AmielTel Aviv University FDFousseny DiakitéDonka Hospital

Discussion

Member takes

Implication

Retrospective study evaluates temozolomide outcomes in low-grade gliomas, suggesting predictive power of chromosome deletions.

Key Points

This research aims to understand how chromosome 1p/19q deletions influence the response and outcomes of low-grade gliomas treated with temozolomide chemotherapy.
Retrospective evaluation of adult patients with progressive low-grade gliomas treated with temozolomide.
Chromosome 1p and 19q deletions detected using loss of heterozygosity technique.
Analysis of response and progression-free survival based on MRI reviews.
53% of patients had an objective response to temozolomide after a median of 14 cycles.
42% of cases showed combined 1p/19q LOH, linked to increased response rate (p=0.02) and longer PFS (p=4.10^(-5)).
Median progression-free survival was 28 months (95% CI: 23.4 to 32.6).

Cite This Study

Kaloshi et al. (2007) studied this question.

synapsesocial.com/papers/6a20d4ebb86afc18201802a3 https://doi.org/10.1212/01.wnl.0000262034.26310.a2

View Full Paper

Ask AI

Bookmark

Temozolomide for low-grade gliomas

Discussion

Member takes

Implication

Key Points

Cite This Study

Temozolomide for low-grade gliomas

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider